Pneumococcal Vaccine Market Size, Share & Trends Analysis Report By Product (PPSV 23, PCV 7/13, and PCV 10), By Applications (Child, Adult), By End Use, By Region, and Segment Forecasts - 2035

PNEUMOCOCCAL VACCINE MARKET OVERVIEW

pneumococcal vaccine market Size was estimated at 7359.49 USD million in 2025, The industry is projected to grow from 7440.44 USD million in 2026 to 7688.69 USD million by 2035, exhibiting a compound annual growth rate (CAGR) of 1.1% during the forecast period 2026 - 2035.

The pneumococcal vaccines market is expected to rise considerably during the forecast period. This is due to the rising knowledge of the diseases that these vaccines can prevent and the increasing support from the government to the activities geared towards the prevention and treatment of pneumococcal disease. The diseases which occur due to the infection from the bacterium, namely streptococcus pneumoniae, commonly known as pneumococcus, such as pneumonia, meningitis, and sepsis, among others, are known to be quite high risk especially in children, elderly, and immunosuppressant patients. The increased usage of these vaccines was associated with the vaccination promotion strategies and development of health systems in developing countries, while the concept of curative preventive health care had wider acceptance earlier across the globe.

Additionally, the heightened demand for biological products is driven by technological innovations in the manufacture of vaccines and therefore the advent of sustained conjugate vaccines. The leading vaccine producers devote much of their research activities to improving the efficacy of currently available vaccines and developing multicomponent formulations that include multiple serotypes of pneumococci. In addition, Bodies like World Health organization (WHO) and others station more or less the same assist in enabling the provision of these vaccines to the populace through the funding of vaccination undertakings, as a result this also increases the demand for the vaccines.

The United States is one of the largest markets for pneumococcal vaccines, driven by comprehensive adult and pediatric immunization programs, high healthcare spending, and increasing awareness of pneumococcal disease prevention. Pneumococcal vaccines are widely administered to protect against invasive pneumococcal diseases, including pneumonia, meningitis, and bloodstream infections, particularly among infants, older adults, and individuals with underlying health conditions. Ongoing recommendations for expanded vaccination coverage, combined with advances in higher-valent conjugate vaccines, are supporting market growth. Continued investments in vaccine research, manufacturing capacity, and immunization infrastructure continue to strengthen the U.S. pneumococcal vaccine market.

• • 

    Download Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Pneumococcal Vaccine Market size was USD 7279.41 Million in 2024, is projected to grow to USD 7321.94 Million by 2025 and exceed USD 7522.28 Million by 2033, with a CAGR of 1.1%

• Key Market Driver: Increased immunization programs worldwide are driving demand—over 150 countries have incorporated pneumococcal vaccines into their national schedules as of 2023.

• Major Market Restraint: Limited cold chain infrastructure in low-income regions remains a challenge, with 30% of vaccine doses at risk due to refrigeration failures, according to WHO data.

• Emerging Trends: Combination vaccines are gaining traction; for example, PCV20 covers 20 serotypes in a single dose, improving patient compliance and reducing clinic visits.

• Regional Leadership: North America leads in uptake, with the U.S. reporting over 90% coverage in children under 2 years old through its VFC (Vaccines for Children) program.

• Competitive Landscape: The market is dominated by a few giants—Pfizer, GSK, and Merck together control over 85% of global supply, creating high entry barriers for new players.

• Market Segmentation: The pediatric segment remains the largest, accounting for more than 60% of doses administered annually due to WHO’s early-childhood immunization push.

• Recent Development: In 2023, Pfizer launched its new Prevnar 20 vaccine across Europe, expanding serotype coverage and offering enhanced protection for older adults.

COVID-19 IMPACT

"Pneumococcal Vaccine Market Had a Negative Effect Due to disruption of routine vaccination programs"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The Pneumococcal Vaccine market, along with others, also faced setbacks during the global pandemic because many routine immunisation programs were affected. The healthcare systems that were hit by the pandemic and adopted measures to control the infection caused discontinuation and deferral of other immunizations like the pneumococcal vaccination. Stopping routine use of the shot raised concerns on the return of infective cases of pneumonia organisms especially for the vulnerable populations. However, with the restoration of healthcare services and the growing awareness on the importance of childhood vaccines, there is a chance that the market will benefit from improved vaccine campaigns in future.

LATEST TREND

"Focus on developing conjugate vaccines that provide broader and longer-lasting immunity to Drive Market Growth"

The expansion of the pneumococcal vaccines market is partly due to the growing consumer consciousness towards vaccination, government intervention in immunization programs, and the quest for multi-strain pneumococcal vaccines. Conjugate vaccines especially for children and older adults, who comprise the at risk populations, do tend to show improvement in characteristics such as scope of protection and duration of protection. Next generation pneumococcal vaccines, which will not only aim to work against strains that are already in circulation, but will also minimize the chances of severe adverse effects becoming apparent, are also in the process of being invented. It also responds to the case of the infection caused by the resistance strain of pneumococcus which is now a pandemic, hence emphasizing the need for broad-spectrum vaccines development.

• • 

    Download Free sample to learn more about this report.

PNEUMOCOCCAL VACCINE MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into PPSV 23, PCV 7/13, and PCV 10

• PPSV 23 : The 23-Valent Pneumococcal Polysaccharide Vaccine is composed of 23 serotypes of the pneumococcus bacteria and thus makes it more applicable in geriatric and certain medical conditions than other vaccines. This vaccine is also advised for older people and high-risk patients in order to protect this population from as many strains of the pathogen causing the disease as possible. The use of this vaccine in the healthcare delivery system has greatly contributed towards addressing morbidity and mortality attributed to pneumonia related hospitalizations in the community.

• PCV 7/13 : Pneumococcal Conjugate Vaccine-7 (PCV-7) and Pneumococcal Conjugate Vaccine-13 (PCV-13) are targeted at infants since they protect against seven and thirteen strains of pneumococcus respectively. These are highly important especially in the prevention of the two serious conditions – meningitis and bacteremia, which are both caused by the pneumococcus germ and are common in young children. After the advent of PCV 13, an improved vaccine which cover additional strains, the decline in pneumococcus diseases has been more pronounced even in the vaccinated populations.

• PCV 10 : Pneumococcal Conjugate Vaccine (PCV 10) protects against ten serotypes of pneumococcal bacteria and is mainly used in childhood. This vaccine prevents severe diseases, such as pneumonia and otitis media in children thus helping to improve the health outcomes of children. Its addition to the routine immunization in different countries has led to a reduction in pneumonia prevalence in children who have received targeted vaccines.

By Application

Based on application, the global market can be categorized into Child, and Adult

• Child : Vaccination of children against pneumococcal disease is one of the measures to prevent the development of invasive diseases such as pneumonia, or meningitis, otitis media, and other diseases caused by organisms of pneumococcus. Among the preventive measures, immunizations such as the pneumococcal vaccination administered in the form of PCV 7, PCV 10, and other forms of pneumococcal vaccination, are among the first vaccines given to children. It has been noted during and after the introduction and use of pneumococcal vaccine in children; the burden of such diseases in children reduced why there is improved health and fewer hospitalizations.

• Adult : Pneumococcal illnesses like pneumonia, which is caused by the pneumococcus bacteria, entail great risk in the age group of over 65 years and the actively healthy population, and everyone in these groups is strongly advised to be immunized, for instance with PCV 13 or PPSV 23. The aim of their introduction is to avoid the development of severe complications and especially infections such as pneumonia, thus minimizing the disability-adjusted life years in the core population. The public health approach to vaccination of adults in particular represents an enhancement of the wellbeing of the population and a reduction in the costs of health care.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

"Increasing Incidence of Pneumococcal Diseases ""to Boost the Market"

The growing prevalence of pneumococcal diseases within at-risk groups, especially in the cases of infants and younger children as well as the aged population, has been a key factor motivating growth in the pneumococcal vaccine market. In response to the increased health risks posed by pneumonia along with other diseases caused by pneumococcus such as meningitis, healthcare practitioners have been encouraging patients to take the vaccines. This increasing awareness and interventions for this cause also helps escalate the Pneumococcal Vaccine market growth, as many people wish to be vaccinated against such dangerous illnesses.

"Expanding Immunization Programs to Expand the Market"

The development of the immunization sector across countries especially the low and middle income has sparked the pneumococcal vaccine market growth. Many health ministries and organizations are emphasizing investments aiming at the introduction of pneumonia vaccines in the country’s health system in a bid to combat infectious diseases. There is increased funding and focus from various international health bodies especially GAVI which is improving access to the vaccines resulting in their increased consumption and stimulating growth of the market in regions that have been previously unmet.

Restraining Factor

"High Cost of Vaccination ""to Potentially Impede Market Growth"

A key limiting factor in the pneumococcal vaccines market is the exorbitant expense associated with vaccination, which restricts access especially within low and middle income countries. The cost of pneumococcal vaccines tends to discourage health care the inclusion of vaccination against pneumococcus in universal immunization programs or result in low vaccination of at risk populations. Furthermore, inadequate health care funds and resources in some areas may frustrate the efforts to carry out such exhaustive vaccination campaigns, which is likely to affect the market expansion adversely.

Opportunity

"Rising Demand for Combination Vaccines to create Opportunity for the product in the market"

An evolving trend in the pneumococcal vaccines market is the growing need for combination vaccines that protect against several diseases. Due to the increasing need for all-round immunization from parents and health care providers for children, vaccines that combine pneumococcal protection with other diseases will enhance the growth of the market. Furthermore, these combination vaccines make it possible to reduce the number of visits for vaccination and adherence to the scheme presents a great chance for the companies to widen their range of products and improve the health of the public.

Challenge

"Vaccine Hesitancy and Misinformation ""Could Be a Potential Challenge for Consumers"

One of the most significant challenges that is restricting the growth of the pneumococcal vaccines market is the hesitance towards vaccination owing to the false beliefs or ignorance regarding the necessity of immunization. False information propagated via social media and other platforms, particularly focused on certain populations, regarding the dangers of vaccines can lead to reduced vaccination levels. Therefore, this is a common issue experienced in the interaction of individuals with health services related to the prevention of the pneumococcal disease and creates major limitations to the efforts of the health care system in improving vaccination coverage and subsequently the overall market.

• • 

    Download Free sampleto learn more about this report.

•  

PNEUMOCOCCAL VACCINE MARKET REGIONAL INSIGHTS

North America

The united states pneumococcal vaccine market is primarily controlled by North America due to the high levels of health care and vaccination, especially in sensitive regimes like children or aged people. The presence of famous companies entailing Merck and Pfizer enables the research and quick availability of new generation pneumococcal vaccines. In addition, the support of the government by means of immunization programs and health policies aids in the availability and use of these vaccinations. Moreover, the rising incidence of awareness regarding the pneumococcal diseases has played a part in the above increase making the region stronger in her market share across the globe.

Europe

The Pneumococcal vaccine market share in Europe is largely enhanced by effective immunization policies coupled with active population-based vaccination that targets at-risk groups. The vaccine approval processes carried out by European Medicines Agency are also very strict and compulsory hence high level of safety and effectiveness is observed in vaccinations enhancing the trust of the public. Additionally, there is a joint effort by governments, healthcare providers and pharmaceutical companies in enabling vaccination and educational campaigns to be effective. The general public’s knowledge on pneumococcal diseases and its preventive strategies has increased hence the uptake levels of the vaccines and this has further increased the dominance of Europe in the market.

Asia

Asia is rapidly growing as the key region in terms of revenue generation in the pneumococcal vaccine market share owing to large population base and increasing health care expenditure. A number of nations in this region are enhancing their vaccination schedules and incorporating pneumococcal vaccines as a result of the increasing prevalence of respiratory complications. Addressing this concern, a number of these countries have entered into helpful alliances with international organizations, GAVI being one of them, which ensures that these low and middle income countries have access to low cost vaccines. In addition, demand is rising with a heightened understanding of vaccine preventable diseases among members of the health sector and the population, economic expansion of the region’s population is expected to propel the market growth in the region.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through continuous research and development of innovative vaccines"

The expansion of the pneumococcal vaccine market is greatly driven by the key industry players who are constantly researching and developing new vaccines. Pfizer and Merck are also making huge efforts to enhance their product mixes by introducing new compositions and combination vaccines that treat more diseases. In addition, core strategic alliances with government entities and health care organizations help in the distribution and access of such vaccines in poorer regions, as these markets are often complained of being undersupplied. Furthermore, these players conduct campaigns and programs that educate the population on the significance of protection, which in turn leads to an increased need and greater health benefits associated with the diseases-causing pneumococcus.

List of Market Players Profiled

• Pfizer - (U.S.)
• GSK - (U.K.)
• MSD - (U.S.)
• Sanofi Pasteur – (France)
• CDIBP - (China)

KEY INDUSTRY DEVELOPMENTS

June 2023: One industrial development in the Pneumococcal Vaccine Market is announced by Pfizer. They introduced the revised 20-valent pneumococcal conjugate vaccine known as PREVNAR 20®. This vaccine is designed to cover 20 pneumonia causing organisms referred to as pneumococcus, this is a considerable increase in coverage unlike the previous versions. PREVNAR 20® is meant to boost immunological protection among adults especially the high risk populations and represents improvement in pneumococcal vaccines. The launch is in response to the increasing risk of pneumococcal disease in the context of worries about antibiotic resistance, with the intention of advancing optimal health prevention in Europe.

Five Recent Developments (2023-2025)

• Pfizer (2023): Expanded the use of its higher-valent pneumococcal conjugate vaccine by supporting broader immunization initiatives and increasing manufacturing capacity to meet growing demand.
• Merck & Co. (2024): Strengthened its pneumococcal vaccine portfolio through expanded commercialization efforts and continued clinical research supporting adult and pediatric vaccination programs.
• Sanofi (2024): Advanced its vaccine research collaborations by investing in next-generation pneumococcal vaccine development and expanding infectious disease prevention initiatives.
• GSK (2025): Enhanced its vaccine research pipeline with continued investment in innovative pneumococcal vaccine technologies and expanded manufacturing capabilities for global supply.
• Serum Institute of India (2025): Increased production capacity for pneumococcal conjugate vaccines and expanded international supply to support broader immunization programs and improve vaccine accessibility.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The Pneumococcal Vaccine Market is poised for a continued boom pushed by increasing health recognition, the growing popularity of plant-based diets, and innovation in product services. Despite challenges, which include confined uncooked fabric availability and better costs, the demand for gluten-unfastened and nutrient-dense alternatives supports marketplace expansion. Key industry players are advancing via technological upgrades and strategic marketplace growth, enhancing the supply and attraction of Launch Vehicle. As customer choices shift towards healthier and numerous meal options, the Pneumococcal Vaccine Market is expected to thrive, with persistent innovation and a broader reputation fueling its destiny prospects.